Understanding Anti-Nuclear Antibodies and Their Role in Autoimmune Disease Screening
Samwel Mikaye, Chief Executive Officer at Samik Medical Center, shared in the Laboratory Professionals International group on LinkedIn:
”Anti-Nuclear Antibody (ANA)
What Are They?
Anti-nuclear antibodies (ANA) are autoantibodies produced by the immune system that mistakenly attack the nucleus of the body’s own cells. The nucleus contains DNA, RNA, and associated proteins, so ANA may target these nuclear components, including nucleotides.
Why Are ANA Tested?
The ANA test is mainly used to screen for autoimmune diseases, especially:
• Systemic Lupus Erythematosus (SLE) — most commonly associated
• Sjögren’s Syndrome
• Scleroderma (Systemic Sclerosis)
• Mixed Connective Tissue Disease
• Autoimmune Thyroid Disorders (sometimes)
• Rheumatoid Arthritis (occasionally)
How Is the Test Reported?
• Results are given as titers, such as 1:40, 1:160, or 1:320.
• A higher titer suggests stronger autoimmune activity.
• The pattern seen in the lab (e.g., homogeneous, speckled, nucleolar, or centromere) may help indicate which autoimmune condition is more likely — but pattern alone is not diagnostic.
Important Interpretation Notes
• A positive ANA does not always mean disease.
• Many healthy individuals, especially elderly or those with infections, may have low-level ANA positivity.
• A negative ANA makes lupus very unlikely, but does not completely rule out all autoimmune disorders.
• Additional specific antibody tests (like anti-dsDNA, anti-Smith, anti-Ro/La) are often required to confirm diagnosis.
Key Takeaways
- ANA are antibodies that react against the body’s own cell nuclei
- Used mainly as a screening tool for autoimmune diseases like lupus
- Positive ANA alone is not enough for diagnosis — symptoms and further tests are essential
- Negative ANA reduces likelihood of lupus significantly.”
Stay updated with Hemostasis Today.
-
Jul 18, 2026, 18:00Karen Schreiber: Advancing Thrombosis Epidemiology Through Global Collaboration at ISTH 2026
-
Jul 18, 2026, 17:34Living With ITP – A New Resource for Navigating Your Diagnosis – ITP Support Association
-
Jul 18, 2026, 17:34Mona Alfaraj: It Was a Hot Week Attending ISTH 2026 Congress in Paris
-
Jul 18, 2026, 17:26Shernan Holtan: Latest Publication on PTCy
-
Jul 18, 2026, 17:20Doaa EL Demerdash: Connecting the Global ITP Community at ISTH 2026
-
Jul 18, 2026, 16:58Isabella Presch: Innovative Trial Designs for Rare Pediatric Studies
-
Jul 18, 2026, 16:36Caitlin Schneider: Research, Collaboration, and New Beginnings at ISTH 2026
-
Jul 18, 2026, 16:23Panagiota Tsiatsiou: Honored to Present Our Research at the ISTH 2026 Congress in Paris
-
Jul 18, 2026, 16:03Robert Tadevosyan: A Week of Science, Collaboration, and Growth at ISTH 2026